Skip to main content

Bone Marrow Transplant Clinical Trials

St. Jude Clinical Trials

CATCHAML: CAR T-Cell Therapy for Acute Myelogenous Leukemia (AML)

Diseases Treated:

Acute Myelogenous Leukemia

Eligibility:

  • 21 years old or younger
  • Relapsed/refractory CD123+ AML, B-ALL, T-ALL or blastic plasmacytoid dendritic cell neoplasm
  • Has a suitable bone marrow transplant donor for allogeneic bone marrow transplant

 

*FDA requires initial participants to be at least 16 years old.

View Trial

HAP2HCT: Partially Matched Family Donor Bone Marrow Transplant in Children and Young Adults with High Risk Cancer

Diseases Treated:

Eligibility:

For transplant recipient:

  • 21 years or younger
  • Does not have a suitable sibling donor or volunteer unrelated donor
  • Has a suitable single haplotype matched family member donor
  • Diagnosed with high risk hematologic malignancy
  • No prior allogeneic hematopoietic cell transplant
View Trial

LVXSCID-ND: Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1) in Newly Diagnosed Infants

Diseases Treated:

X-linked Severe Combined Immunodeficiency (SCID-X1)

Eligibility:

  • Diagnosis of Severe Combined Immunodeficiency, X-linked (SCID-X1)
  • Newborn to 2 years of age
  • No prior therapy with allogeneic stem cell transplantation
  • No HIV infection
View Trial

MEMCAR19: Allogeneic CAR T-Cell Therapy for Relapsed/Refractory CD19-Positive Leukemia

Diseases Treated:

Acute lymphoblastic leukemia

Eligibility:

Donor eligibility includes:

  • At least 18 years old
  • At least single haplotype matched family member

Recipient eligibility includes:

  • 21 years old or younger*
  • Diagnosed with relapsed and/or refractory CD19-positive leukemia
  • Not suitable for autologous CD19-CAR T-cell therapy

* Initial 3 participants must be at least 16 years old.

View Trial

REF2HCT: Haploidentical Bone Marrow Transplant for Leukemia and Lymphoma

Diseases Treated:

Eligibility:

  • 21 years old and younger
  • Diagnosed with one of the following that has come back or did not improve after bone marrow transplant
    • Acute lymphoblastic leukemia (ALL)
    • Acute myeloid leukemia
    • Myeloid sarcoma
    • Chronic myeloid leukemia (CML)
    • Juvenile myelomonocytic leukemia (JMML)
    • Myelodysplastic syndrome (MDS)
    • Non-Hodgkin lymphoma (NHL)
  • Has a family member who is a suitable stem cell donor
View Trial

SCDHCT: Reduced Intensity Related Donor HCT for Patients with Severe Sickle Cell Disease

Diseases Treated:

Sickle Cell Disease

Eligibility:

  • 25 years old or younger
  • Diagnosed with severe sickle cell disease
  • Has a suitable HLA-matched sibling donor or single haplotype matched (half matched) family member donor (parents or siblings)
View Trial

SCIDBMT: Bone Marrow Transplant for Infants with Severe Combined Immunodeficiency (SCID)

Diseases Treated:

Severe combined immunodeficiency (SCID)

Eligibility:

  • Infant at least 2 months old with severe combined immunodeficiency (SCID)
  • Has suitable matched sibling donor or matched unrelated donor or a single haplotype matched family member donor
View Trial

SJCAR19: CAR T-Cell Therapy for Children and Young Adults with Acute Lymphoblastic Leukemia

Diseases Treated:

Acute lymphoblastic leukemia

Eligibility:

 

 

View Trial

Collaborative Clinic Trials

None at this time.